Literature DB >> 26069279

Adjuvant Therapy Reduces Rate of Dissemination but Shortens Survival Thereafter.

Michael K Fink1, Ulrich R Kleeberg2, Stefan Bartels3.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26069279      PMCID： PMC4492238          DOI： 10.1634/theoncologist.2015-0116

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  8 in total

1.  The 2011 EBCTCG polychemotherapy overview.

Authors:  Carlo Palmieri; Alison Jones
Journal:  Lancet       Date:  2011-12-05       Impact factor: 79.321

2.  Adjuvant therapy-related shortening of survival (ATRESS): an underrated phenomenon.

Authors:  Michael K Fink; Ulrich R Kleeberg; Stefan Bartels
Journal:  Oncologist       Date:  2015-01

3.  In reply.

Authors:  Binghe Xu; Andrew Seidman; Stephen Chan
Journal:  Oncologist       Date:  2015-01

4.  Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy.

Authors:  J Y Pierga; B Asselain; M Jouve; V Diéras; M Carton; V Laurence; V Girre; P Beuzeboc; T Palangié; T Dorval; P Pouillart
Journal:  Cancer       Date:  2001-03-15       Impact factor: 6.860

5.  Combination chemotherapy as an adjuvant treatment in operable breast cancer.

Authors:  G Bonadonna; E Brusamolino; P Valagussa; A Rossi; L Brugnatelli; C Brambilla; M De Lena; G Tancini; E Bajetta; R Musumeci; U Veronesi
Journal:  N Engl J Med       Date:  1976-02-19       Impact factor: 91.245

6.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Authors:  Kathy Miller; Molin Wang; Julie Gralow; Maura Dickler; Melody Cobleigh; Edith A Perez; Tamara Shenkier; David Cella; Nancy E Davidson
Journal:  N Engl J Med       Date:  2007-12-27       Impact factor: 91.245

Review 7.  Adjuvant therapy reduces the benefit of palliative treatment in disseminated breast cancer - own findings and review of the literature.

Authors:  Ulrich R Kleeberg; Michael Fink; Hans-Werner Tessen; Alice Nennecke; Stefan Hentschel; Stefan Bartels
Journal:  Onkologie       Date:  2013-05-21

8.  A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer.

Authors:  Andrew D Seidman; Stephen Chan; Jin Wang; Chao Zhu; Cong Xu; Binghe Xu
Journal:  Oncologist       Date:  2014-04-04
  8 in total
  2 in total

1.  Invasive breast cancer over four decades reveals persisting poor metastatic outcomes in treatment resistant subgroup - the "ATRESS" phenomenon.

Authors:  Patriek Jurrius; Thomas Green; Hans Garmo; Matthew Young; Massimiliano Cariati; Cheryl Gillett; Anca Mera; Mark Harries; Anita Grigoriadis; Sarah Pinder; Lars Holmberg; Arnie Purushotham
Journal:  Breast       Date:  2020-01-14       Impact factor: 4.380

2.  Does adjuvant therapy reduce postmetastatic survival?

Authors:  M K Fink
Journal:  Ann Oncol       Date:  2019-08-01       Impact factor: 32.976
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.